[{"run_id":"20260906T231458-5fdd2fff","observed_at":"2026-09-06 23:14:58.172943+00:00","course_uid":"course_b7da72aecf53dbf40a363e61","course_id":"PHMSCI 763","catalog_version_id":"9175f1759595135dffb4d3a74fa30fbc555bdc5afa3f29449dd1c84a8a860282","record_version_id":"ba5f1ea43fbd75baa388ed7fe49ee45cbb5b1fdbcdbd5df71a084fc673984f7c","job_id":"enrich-5291a20b802b9bbbe22b24cb","output_id":"2c00c555958f8b6113d3b21aa005e8b4534631005fa93e929a18d717b42dabf8","section":"requirements","status":"invalid","value_json":null,"candidate_json":"{\"nodes\":[{\"children\":[],\"condition\":null,\"course\":null,\"evidence\":\"Declared in MS Pharmaceutical Sciences: Applied Drug Development or Capstone Certificate in Applied Drug Development\",\"id\":\"n0\",\"kind\":\"any\"}],\"notes\":[],\"root\":\"n0\",\"status\":\"parsed\"}","error":"Boolean groups require at least two children","model":"nvidia/Qwen3.6-35B-A3B-NVFP4","model_revision":"1355db6a052410cfd62085d94b58866fd0f2c3c5","selected_for_release":false},{"run_id":"20260906T231458-5fdd2fff","observed_at":"2026-09-06 23:14:58.172943+00:00","course_uid":"course_b7da72aecf53dbf40a363e61","course_id":"PHMSCI 763","catalog_version_id":"9175f1759595135dffb4d3a74fa30fbc555bdc5afa3f29449dd1c84a8a860282","record_version_id":"ba5f1ea43fbd75baa388ed7fe49ee45cbb5b1fdbcdbd5df71a084fc673984f7c","job_id":"enrich-5291a20b802b9bbbe22b24cb","output_id":"2c00c555958f8b6113d3b21aa005e8b4534631005fa93e929a18d717b42dabf8","section":"search_profile","status":"valid","value_json":"{\"assumed_background\":[],\"search_phrases\":[\"drug development process\",\"clinical trials phases\",\"biomarkers diagnostics\",\"CMC clinical trials\",\"small molecule protein therapeutics\",\"NDA BLA submission\"],\"skills_taught\":[{\"evidence\":[{\"course_id\":\"PHMSCI 763\",\"field\":\"description\",\"quote\":\"Overview of the drug development process from first-in-human (FIH) to submission of a new drug application (NDA) or biologics license application (BLA)\"}],\"text\":\"Understanding the end-to-end drug development lifecycle from initial human trials to regulatory submission\"},{\"evidence\":[{\"course_id\":\"PHMSCI 763\",\"field\":\"description\",\"quote\":\"Phases of clinical development and the role of biomarkers, companion diagnostics, statistical analysis, and CMC in clinical trials\"}],\"text\":\"Analyzing the roles of biomarkers, diagnostics, statistics, and CMC within clinical trial phases\"}],\"summary\":{\"evidence\":[{\"course_id\":\"PHMSCI 763\",\"field\":\"title\",\"quote\":\"THE DRUG DEVELOPMENT PROCESS FROM FIH TO BLA/NDA\"},{\"course_id\":\"PHMSCI 763\",\"field\":\"description\",\"quote\":\"Overview of the drug development process from first-in-human (FIH) to submission of a new drug application (NDA) or biologics license application (BLA)\"}],\"text\":\"PHMSCI 763 covers the drug development process from first-in-human trials to NDA/BLA submission, addressing clinical phases, biomarkers, and therapeutics.\"},\"topics\":[{\"evidence\":[{\"course_id\":\"PHMSCI 763\",\"field\":\"description\",\"quote\":\"Phases of clinical development\"}],\"text\":\"Phases of clinical development\"},{\"evidence\":[{\"course_id\":\"PHMSCI 763\",\"field\":\"description\",\"quote\":\"role of biomarkers, companion diagnostics, statistical analysis, and CMC in clinical trials\"}],\"text\":\"Biomarkers, companion diagnostics, statistical analysis, and CMC\"},{\"evidence\":[{\"course_id\":\"PHMSCI 763\",\"field\":\"description\",\"quote\":\"Both small molecule and protein therapeutics will be addressed\"}],\"text\":\"Small molecule and protein therapeutics\"}]}","candidate_json":null,"error":null,"model":"nvidia/Qwen3.6-35B-A3B-NVFP4","model_revision":"1355db6a052410cfd62085d94b58866fd0f2c3c5","selected_for_release":false},{"run_id":"20260906T231458-5fdd2fff","observed_at":"2026-09-06 23:14:58.172943+00:00","course_uid":"course_b7da72aecf53dbf40a363e61","course_id":"PHMSCI 763","catalog_version_id":"9175f1759595135dffb4d3a74fa30fbc555bdc5afa3f29449dd1c84a8a860282","record_version_id":"ba5f1ea43fbd75baa388ed7fe49ee45cbb5b1fdbcdbd5df71a084fc673984f7c","job_id":"enrich-5291a20b802b9bbbe22b24cb","output_id":"2c00c555958f8b6113d3b21aa005e8b4534631005fa93e929a18d717b42dabf8","section":"student_experience","status":"insufficient_evidence","value_json":"{\"status\":\"insufficient_evidence\",\"themes\":[]}","candidate_json":null,"error":null,"model":"nvidia/Qwen3.6-35B-A3B-NVFP4","model_revision":"1355db6a052410cfd62085d94b58866fd0f2c3c5","selected_for_release":false},{"run_id":"20260907T155543-ce3781c4","observed_at":"2026-09-07 15:55:43.033547+00:00","course_uid":"course_b7da72aecf53dbf40a363e61","course_id":"PHMSCI 763","catalog_version_id":"9175f1759595135dffb4d3a74fa30fbc555bdc5afa3f29449dd1c84a8a860282","record_version_id":"ba5f1ea43fbd75baa388ed7fe49ee45cbb5b1fdbcdbd5df71a084fc673984f7c","job_id":"enrich-5590a4969e0a630fe46a86e8","output_id":"c16f06e25019cc6c4d774676ebeec9760eeac2cff9cd0d061a55123eefbf3a12","section":"requirements","status":"valid","value_json":"{\"nodes\":[{\"children\":[],\"condition\":\"Declared in MS Pharmaceutical Sciences: Applied Drug Development or Capstone Certificate in Applied Drug Development\",\"course\":null,\"evidence\":\"Declared in MS Pharmaceutical Sciences: Applied Drug Development or Capstone Certificate in Applied Drug Development\",\"id\":\"n0\",\"kind\":\"condition\"}],\"notes\":[],\"root\":\"n0\",\"status\":\"parsed\"}","candidate_json":null,"error":null,"model":"nvidia/Qwen3.6-35B-A3B-NVFP4","model_revision":"1355db6a052410cfd62085d94b58866fd0f2c3c5","selected_for_release":true},{"run_id":"20260907T155543-ce3781c4","observed_at":"2026-09-07 15:55:43.033547+00:00","course_uid":"course_b7da72aecf53dbf40a363e61","course_id":"PHMSCI 763","catalog_version_id":"9175f1759595135dffb4d3a74fa30fbc555bdc5afa3f29449dd1c84a8a860282","record_version_id":"ba5f1ea43fbd75baa388ed7fe49ee45cbb5b1fdbcdbd5df71a084fc673984f7c","job_id":"enrich-5590a4969e0a630fe46a86e8","output_id":"c16f06e25019cc6c4d774676ebeec9760eeac2cff9cd0d061a55123eefbf3a12","section":"search_profile","status":"valid","value_json":"{\"assumed_background\":[],\"search_phrases\":[\"drug development process\",\"clinical trials phases\",\"biomarkers diagnostics\",\"CMC clinical trials\",\"small molecule protein therapeutics\",\"NDA BLA submission\"],\"skills_taught\":[{\"evidence\":[{\"course_id\":\"PHMSCI 763\",\"field\":\"description\",\"quote\":\"Overview of the drug development process from first-in-human (FIH) to submission of a new drug application (NDA) or biologics license application (BLA)\"}],\"text\":\"Understanding the end-to-end drug development lifecycle from initial human trials to regulatory submission\"},{\"evidence\":[{\"course_id\":\"PHMSCI 763\",\"field\":\"description\",\"quote\":\"Phases of clinical development and the role of biomarkers, companion diagnostics, statistical analysis, and CMC in clinical trials\"}],\"text\":\"Analyzing the roles of biomarkers, diagnostics, statistics, and CMC within clinical trial phases\"}],\"summary\":{\"evidence\":[{\"course_id\":\"PHMSCI 763\",\"field\":\"title\",\"quote\":\"THE DRUG DEVELOPMENT PROCESS FROM FIH TO BLA/NDA\"},{\"course_id\":\"PHMSCI 763\",\"field\":\"description\",\"quote\":\"Overview of the drug development process from first-in-human (FIH) to submission of a new drug application (NDA) or biologics license application (BLA)\"}],\"text\":\"PHMSCI 763 covers the drug development process from first-in-human trials to NDA/BLA submission, addressing clinical phases, biomarkers, and therapeutics.\"},\"topics\":[{\"evidence\":[{\"course_id\":\"PHMSCI 763\",\"field\":\"description\",\"quote\":\"Phases of clinical development\"}],\"text\":\"Phases of clinical development\"},{\"evidence\":[{\"course_id\":\"PHMSCI 763\",\"field\":\"description\",\"quote\":\"role of biomarkers, companion diagnostics, statistical analysis, and CMC in clinical trials\"}],\"text\":\"Biomarkers, companion diagnostics, statistical analysis, and CMC\"},{\"evidence\":[{\"course_id\":\"PHMSCI 763\",\"field\":\"description\",\"quote\":\"Both small molecule and protein therapeutics will be addressed\"}],\"text\":\"Small molecule and protein therapeutics\"}]}","candidate_json":null,"error":null,"model":"nvidia/Qwen3.6-35B-A3B-NVFP4","model_revision":"1355db6a052410cfd62085d94b58866fd0f2c3c5","selected_for_release":true},{"run_id":"20260907T155543-ce3781c4","observed_at":"2026-09-07 15:55:43.033547+00:00","course_uid":"course_b7da72aecf53dbf40a363e61","course_id":"PHMSCI 763","catalog_version_id":"9175f1759595135dffb4d3a74fa30fbc555bdc5afa3f29449dd1c84a8a860282","record_version_id":"ba5f1ea43fbd75baa388ed7fe49ee45cbb5b1fdbcdbd5df71a084fc673984f7c","job_id":"enrich-5590a4969e0a630fe46a86e8","output_id":"c16f06e25019cc6c4d774676ebeec9760eeac2cff9cd0d061a55123eefbf3a12","section":"student_experience","status":"insufficient_evidence","value_json":"{\"status\":\"insufficient_evidence\",\"themes\":[]}","candidate_json":null,"error":null,"model":"nvidia/Qwen3.6-35B-A3B-NVFP4","model_revision":"1355db6a052410cfd62085d94b58866fd0f2c3c5","selected_for_release":true},{"run_id":"20260906T231458-5fdd2fff","observed_at":"2026-09-06 23:14:58.172943+00:00","course_uid":"course_b7da72aecf53dbf40a363e61","course_id":"PHMSCI 763","catalog_version_id":"9175f1759595135dffb4d3a74fa30fbc555bdc5afa3f29449dd1c84a8a860282","record_version_id":"ba5f1ea43fbd75baa388ed7fe49ee45cbb5b1fdbcdbd5df71a084fc673984f7c","job_id":"enrich-789789da373eecc1ff75f626","output_id":"6474954471aa885be945510330f9ddfbf6407fc22f2e2e3cd82761052b4e05d2","section":"requirements","status":"needs_review","value_json":"{\"nodes\":[{\"children\":[],\"condition\":\"Declared in MS Pharmaceutical Sciences: Applied Drug Development or Capstone Certificate in Applied Drug Development\",\"course\":null,\"evidence\":\"Declared in MS Pharmaceutical Sciences: Applied Drug Development or Capstone Certificate in Applied Drug Development\",\"id\":\"n0\",\"kind\":\"condition\"}],\"notes\":[],\"root\":\"n0\",\"status\":\"parsed\"}","candidate_json":null,"error":null,"model":"nvidia/Qwen3.6-35B-A3B-NVFP4","model_revision":"1355db6a052410cfd62085d94b58866fd0f2c3c5","selected_for_release":false},{"run_id":"20260906T231458-5fdd2fff","observed_at":"2026-09-06 23:14:58.172943+00:00","course_uid":"course_b7da72aecf53dbf40a363e61","course_id":"PHMSCI 763","catalog_version_id":"9175f1759595135dffb4d3a74fa30fbc555bdc5afa3f29449dd1c84a8a860282","record_version_id":"ba5f1ea43fbd75baa388ed7fe49ee45cbb5b1fdbcdbd5df71a084fc673984f7c","job_id":"enrich-789789da373eecc1ff75f626","output_id":"6474954471aa885be945510330f9ddfbf6407fc22f2e2e3cd82761052b4e05d2","section":"search_profile","status":"valid","value_json":"{\"assumed_background\":[],\"search_phrases\":[\"drug development process\",\"clinical trials phases\",\"biomarkers diagnostics\",\"CMC clinical trials\",\"small molecule protein therapeutics\",\"NDA BLA submission\"],\"skills_taught\":[{\"evidence\":[{\"course_id\":\"PHMSCI 763\",\"field\":\"description\",\"quote\":\"Overview of the drug development process from first-in-human (FIH) to submission of a new drug application (NDA) or biologics license application (BLA)\"}],\"text\":\"Understanding the end-to-end drug development lifecycle from initial human trials to regulatory submission\"},{\"evidence\":[{\"course_id\":\"PHMSCI 763\",\"field\":\"description\",\"quote\":\"Phases of clinical development and the role of biomarkers, companion diagnostics, statistical analysis, and CMC in clinical trials\"}],\"text\":\"Analyzing the roles of biomarkers, diagnostics, statistics, and CMC within clinical trial phases\"}],\"summary\":{\"evidence\":[{\"course_id\":\"PHMSCI 763\",\"field\":\"title\",\"quote\":\"THE DRUG DEVELOPMENT PROCESS FROM FIH TO BLA/NDA\"},{\"course_id\":\"PHMSCI 763\",\"field\":\"description\",\"quote\":\"Overview of the drug development process from first-in-human (FIH) to submission of a new drug application (NDA) or biologics license application (BLA)\"}],\"text\":\"PHMSCI 763 covers the drug development process from first-in-human trials to NDA/BLA submission, addressing clinical phases, biomarkers, and therapeutics.\"},\"topics\":[{\"evidence\":[{\"course_id\":\"PHMSCI 763\",\"field\":\"description\",\"quote\":\"Phases of clinical development\"}],\"text\":\"Phases of clinical development\"},{\"evidence\":[{\"course_id\":\"PHMSCI 763\",\"field\":\"description\",\"quote\":\"role of biomarkers, companion diagnostics, statistical analysis, and CMC in clinical trials\"}],\"text\":\"Biomarkers, companion diagnostics, statistical analysis, and CMC\"},{\"evidence\":[{\"course_id\":\"PHMSCI 763\",\"field\":\"description\",\"quote\":\"Both small molecule and protein therapeutics will be addressed\"}],\"text\":\"Small molecule and protein therapeutics\"}]}","candidate_json":null,"error":null,"model":"nvidia/Qwen3.6-35B-A3B-NVFP4","model_revision":"1355db6a052410cfd62085d94b58866fd0f2c3c5","selected_for_release":false},{"run_id":"20260906T231458-5fdd2fff","observed_at":"2026-09-06 23:14:58.172943+00:00","course_uid":"course_b7da72aecf53dbf40a363e61","course_id":"PHMSCI 763","catalog_version_id":"9175f1759595135dffb4d3a74fa30fbc555bdc5afa3f29449dd1c84a8a860282","record_version_id":"ba5f1ea43fbd75baa388ed7fe49ee45cbb5b1fdbcdbd5df71a084fc673984f7c","job_id":"enrich-789789da373eecc1ff75f626","output_id":"6474954471aa885be945510330f9ddfbf6407fc22f2e2e3cd82761052b4e05d2","section":"student_experience","status":"insufficient_evidence","value_json":"{\"status\":\"insufficient_evidence\",\"themes\":[]}","candidate_json":null,"error":null,"model":"nvidia/Qwen3.6-35B-A3B-NVFP4","model_revision":"1355db6a052410cfd62085d94b58866fd0f2c3c5","selected_for_release":false},{"run_id":"20260907T155543-ce3781c4","observed_at":"2026-09-07 15:55:43.033547+00:00","course_uid":"course_b7da72aecf53dbf40a363e61","course_id":"PHMSCI 763","catalog_version_id":"9175f1759595135dffb4d3a74fa30fbc555bdc5afa3f29449dd1c84a8a860282","record_version_id":"ba5f1ea43fbd75baa388ed7fe49ee45cbb5b1fdbcdbd5df71a084fc673984f7c","job_id":"enrich-8b774950c2b6adfdc46d1b82","output_id":"d2e417dcf56ac41578787954ca4185d0f53f17dff00d090bdb096d53f031fee1","section":"requirements","status":"valid","value_json":"{\"nodes\":[{\"children\":[],\"condition\":\"Declared in MS Pharmaceutical Sciences: Applied Drug Development or Capstone Certificate in Applied Drug Development\",\"course\":null,\"evidence\":\"Declared in MS Pharmaceutical Sciences: Applied Drug Development or Capstone Certificate in Applied Drug Development\",\"id\":\"n0\",\"kind\":\"condition\"}],\"notes\":[],\"root\":\"n0\",\"status\":\"parsed\"}","candidate_json":null,"error":null,"model":"nvidia/Qwen3.6-35B-A3B-NVFP4","model_revision":"1355db6a052410cfd62085d94b58866fd0f2c3c5","selected_for_release":true},{"run_id":"20260907T155543-ce3781c4","observed_at":"2026-09-07 15:55:43.033547+00:00","course_uid":"course_b7da72aecf53dbf40a363e61","course_id":"PHMSCI 763","catalog_version_id":"9175f1759595135dffb4d3a74fa30fbc555bdc5afa3f29449dd1c84a8a860282","record_version_id":"ba5f1ea43fbd75baa388ed7fe49ee45cbb5b1fdbcdbd5df71a084fc673984f7c","job_id":"enrich-8b774950c2b6adfdc46d1b82","output_id":"d2e417dcf56ac41578787954ca4185d0f53f17dff00d090bdb096d53f031fee1","section":"search_profile","status":"valid","value_json":"{\"assumed_background\":[],\"search_phrases\":[\"drug development process\",\"clinical trials phases\",\"biomarkers diagnostics\",\"CMC clinical trials\",\"small molecule protein therapeutics\",\"NDA BLA submission\"],\"skills_taught\":[{\"evidence\":[{\"course_id\":\"PHMSCI 763\",\"field\":\"description\",\"quote\":\"Overview of the drug development process from first-in-human (FIH) to submission of a new drug application (NDA) or biologics license application (BLA)\"}],\"text\":\"Understanding the end-to-end drug development lifecycle from initial human trials to regulatory submission\"},{\"evidence\":[{\"course_id\":\"PHMSCI 763\",\"field\":\"description\",\"quote\":\"Phases of clinical development and the role of biomarkers, companion diagnostics, statistical analysis, and CMC in clinical trials\"}],\"text\":\"Analyzing the roles of biomarkers, diagnostics, statistics, and CMC within clinical trial phases\"}],\"summary\":{\"evidence\":[{\"course_id\":\"PHMSCI 763\",\"field\":\"title\",\"quote\":\"THE DRUG DEVELOPMENT PROCESS FROM FIH TO BLA/NDA\"},{\"course_id\":\"PHMSCI 763\",\"field\":\"description\",\"quote\":\"Overview of the drug development process from first-in-human (FIH) to submission of a new drug application (NDA) or biologics license application (BLA)\"}],\"text\":\"PHMSCI 763 covers the drug development process from first-in-human trials to NDA/BLA submission, addressing clinical phases, biomarkers, and therapeutics.\"},\"topics\":[{\"evidence\":[{\"course_id\":\"PHMSCI 763\",\"field\":\"description\",\"quote\":\"Phases of clinical development\"}],\"text\":\"Phases of clinical development\"},{\"evidence\":[{\"course_id\":\"PHMSCI 763\",\"field\":\"description\",\"quote\":\"role of biomarkers, companion diagnostics, statistical analysis, and CMC in clinical trials\"}],\"text\":\"Biomarkers, companion diagnostics, statistical analysis, and CMC\"},{\"evidence\":[{\"course_id\":\"PHMSCI 763\",\"field\":\"description\",\"quote\":\"Both small molecule and protein therapeutics will be addressed\"}],\"text\":\"Small molecule and protein therapeutics\"}]}","candidate_json":null,"error":null,"model":"nvidia/Qwen3.6-35B-A3B-NVFP4","model_revision":"1355db6a052410cfd62085d94b58866fd0f2c3c5","selected_for_release":true},{"run_id":"20260907T155543-ce3781c4","observed_at":"2026-09-07 15:55:43.033547+00:00","course_uid":"course_b7da72aecf53dbf40a363e61","course_id":"PHMSCI 763","catalog_version_id":"9175f1759595135dffb4d3a74fa30fbc555bdc5afa3f29449dd1c84a8a860282","record_version_id":"ba5f1ea43fbd75baa388ed7fe49ee45cbb5b1fdbcdbd5df71a084fc673984f7c","job_id":"enrich-8b774950c2b6adfdc46d1b82","output_id":"d2e417dcf56ac41578787954ca4185d0f53f17dff00d090bdb096d53f031fee1","section":"student_experience","status":"insufficient_evidence","value_json":"{\"status\":\"insufficient_evidence\",\"themes\":[]}","candidate_json":null,"error":null,"model":"nvidia/Qwen3.6-35B-A3B-NVFP4","model_revision":"1355db6a052410cfd62085d94b58866fd0f2c3c5","selected_for_release":true},{"run_id":"20260907T155543-ce3781c4","observed_at":"2026-09-07 15:55:43.033547+00:00","course_uid":"course_b7da72aecf53dbf40a363e61","course_id":"PHMSCI 763","catalog_version_id":"9175f1759595135dffb4d3a74fa30fbc555bdc5afa3f29449dd1c84a8a860282","record_version_id":"ba5f1ea43fbd75baa388ed7fe49ee45cbb5b1fdbcdbd5df71a084fc673984f7c","job_id":"enrich-8b774950c2b6adfdc46d1b82","output_id":"d2e417dcf56ac41578787954ca4185d0f53f17dff00d090bdb096d53f031fee1","section":"student_summary","status":"valid","value_json":"{\"context_hash\":\"98146676635ec80db84182ced9d35014301fbf1d31eadae7d8e49782de53db13\",\"course_id\":\"PHMSCI 763\",\"current_instructors\":[],\"difficulty_workload\":[],\"errors\":[],\"historical_context\":[],\"message\":\"No course-specific reviews available\",\"offered\":false,\"profile_hash\":\"5cb4dabf887cdbcd8c00d5a1312e10828b95c63f30bc3ea76aea199565390d02\",\"quick_take\":[{\"citations\":[{\"course_id\":\"PHMSCI 763\",\"run_id\":\"20260907T155543-ce3781c4\",\"source_record\":{\"entity_id\":\"0c4e1947-79bd-3097-93c6-dd701cfd65fb\",\"file\":\"tables/observations.parquet\",\"kind\":\"grades\",\"source\":\"madgrades\"},\"table\":\"grades_latest\",\"term_id\":\"1252\",\"type\":\"grade\"},{\"course_id\":\"PHMSCI 763\",\"run_id\":\"20260907T155543-ce3781c4\",\"source_record\":{\"entity_id\":\"0c4e1947-79bd-3097-93c6-dd701cfd65fb\",\"file\":\"tables/observations.parquet\",\"kind\":\"grades\",\"source\":\"madgrades\"},\"table\":\"grades_latest\",\"term_id\":\"1254\",\"type\":\"grade\"},{\"course_id\":\"PHMSCI 763\",\"run_id\":\"20260907T155543-ce3781c4\",\"source_record\":{\"entity_id\":\"0c4e1947-79bd-3097-93c6-dd701cfd65fb\",\"file\":\"tables/observations.parquet\",\"kind\":\"grades\",\"source\":\"madgrades\"},\"table\":\"grades_latest\",\"term_id\":\"1264\",\"type\":\"grade\"}],\"text\":\"Recent recorded grades — Fall 2024: 3.89 GPA, 100.0% A/AB (n=9 letter grades); Spring 2025: 3.75 GPA, 92.9% A/AB (n=28 letter grades); Spring 2026: 3.93 GPA, 100.0% A/AB (n=27 letter grades).\"}],\"student_experience\":[],\"task_hash\":\"74fb0997943e888960bbc9e47db8c4fd12e4292d55c20509d8d89db6a9910f68\",\"teaching_history\":[],\"term_id\":\"1272\",\"term_name\":\"2026 Fall\",\"version\":2}","candidate_json":null,"error":null,"model":"nvidia/Qwen3.6-35B-A3B-NVFP4","model_revision":"1355db6a052410cfd62085d94b58866fd0f2c3c5","selected_for_release":true}]